key: cord-0034718-ypg9rvao authors: Bertz, Hartmut; Henß, Hartmut; Lubrich, Beate title: Hematological and Oncological Emergencies date: 2008 journal: Concise Manual of Hematology and Oncology DOI: 10.1007/978-3-540-73277-8_9 sha: e7e7d9137300fc4f6fd96d0208f4052dce65c2c2 doc_id: 34718 cord_uid: ypg9rvao nan • Chest x-ray, possibly x-ray of paranasal air sinuses • Abdominal ultrasound if indicated • High-resolution CT scan if indicated With fever during neutropenia, rapid initiation of treatment is essential: 1. Microbiological analysis 2. Immediate initiation of empirical antibiotic treatment: broad-spectrum antibiotic with effectiveness against pseudomonas spp., where applicable in combination with an aminoglycoside and a glycopeptide (particularly in case of catheter sepsis). Rapid escalation with antimycotics has proven benefit (amphotericin B, lipid formulation amphotericin B, azoles, echinocandins) (7 Chap. 4 .2) 3. Optimization of tissue oxygenation. Administration of oxygen via nasal tube or mask, 2 l/min up to 12 l/min. Where applicable, respiration support (non-invasive: CPAP; invasive: intubation) 4. Volume substitution; where applicable, administration of catecholamines 5. Initiate intensive medical care at an early stage • Further diagnosis (imaging, ultrasound, bronchoalveolar lavage (BAL), abscess aspiration / biopsy, etc.) • In case of impaired renal function, initiate dialysis • If persistence of neutropenia is expected, administer G-CSF to support bone marrow reconstitution. (7 Chap. 4.3) . Activated protein C demonstrated a positive effect on the overall survival of septic patients, but with marked side effects. Consider granulocyte transfusion (7 Chap. 5.4) . • Basic hospital hygiene; conduct of invasive procedures under aseptic conditions • Patient hygiene, especially skin care, dental care, mucositis prophylaxis; avoid foods with high germ counts • If neutropenia persists for more than 7 days: regular monitoring, even if apyrexial → blood cultures, fecal cultures, throat swabs, sputum. Consequent treatment of fever in neutropenia (7 Chap. 4 .2) • Administration of hematopoietic growth factors (G-CSF) according to current guidelines (ASCO / ESMO guideline; (7 Chap. 4.3) Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Occurrence with various solid tumors and hematological neoplasia → most common: lung cancer, breast cancer, prostate cancer, melanoma, lymphoma, multiple myeloma. Usually extracordal compression of spinal cord or cauda equina: • Tumor invasion from the vertebral body into the epidural space → spinal cord compression (common with lung cancer, breast cancer) • Tumor invasion through the intervertebral foramina → spinal cord compression or nerve root compression (lymphoma) • Direct metastasis into the spinal canal (rare) • Tumor-induced vascular damage → malperfusion, spinal cord damage due to infarction • Paraneoplastic syndromes (7 Chap. 8.13) Location of spinal cord compression: • Cervical: 10% • Thoracic: 70% • Lumbosacral: 20% • Multifocal: 25% Often protracted process over a longer period of time, however, neurological deficits may develop within a few hours (especially with rapidly proliferating neoplasia such as lung cancer, renal cell carcinoma, melanoma, or lymphoma). • Most common symptom: pain (> 90% of patients) as "back ache, " "lumbar syndrome, " etc. • Radicular deficits: dermatoma-specific sensory and motor deficits; band-like pain; in some cases unilateral • Segmental myelopathy: motor deficits / paresis, segmental sensory deficits • Generalized myelopathy: bilateral motor disorders / pareses, sensory deficits; compression around cauda equina: "saddle anesthesia, " bladder / colon paralysis, anal sphincter tone ↓, tendon reflexes ↑, positive Babinski's sign Severe hemodynamically significant pericardial effusion caused by tumor invasion of the pericardium or myocardium. Medical emergency. Invasion of pericardium or myocardium in up to 15% of patients with solid tumors. Direct invasion or lymphatic / hematogenous metastasis to the pericardium or myocardium in patients with solid tumors and hematological neoplasia. Metastasis to the pericardium / myocardium → Pericardial effusion, arrhythmia → Cardiac tamponade (critical effusion volume in cases of rapid onset: 300-400 ml) → Diastolic dysfunction ( Physical examination: rise in jugular venous pressure (increased on inspiration = Kussmaul's sign), pulsus paradoxus (end-inspiratory decrease in blood pressure by > 10 mmHg), muffled heart sounds, pulmonary rales, hepatosplenomegaly, ascites, edema • Chest x-ray: enlarged heart silhouette • ECG changes are usually unspecific, sometimes electrical alternans and/or precordial low voltage; with concurrent pericarditis: sinus tachycardia, raised ST, changes in T-wave • Echocardiography (most important diagnostic tool) • In selected cases: right heart catheterization, angiocardiography • Osteoclast activation and proliferation → increased bone destruction, calcium release • Inhibition of osteoblast activity → reduced bone regeneration • Glomerular filtration rate ↓ , tubular calcium reabsorption ↑ The majority of patients with moderate hypercalcemia are asymptomatic. Symptoms of advanced hypercalcemia (> 2.7 mmol/l) or hypercalcemic crisis (> 3.5 mmol/l): Hyperuricemia: • Rasburicase (recombinant urate oxidase) 0.2 mg/kg/day, for 5-7 days. ATTEN-TION: for measurement of uric acid during treatment with rasburicase use cooled serum; otherwise inaccurate (low) readings. Renal dysfunction / acute oliguria: • Dopamine 100-200 mg/24 h (infusion pump); benefit not fully established. • Dialysis (after exclusion of urinary tract obstruction) Close monitoring: ECG, central venous pressure (CVP, target: > 5), routine laboratory tests (urea + electrolytes, serum creatinine, bilirubin, uric acid) • Identification of high-risk patients (acute leukemias, Burkitt's lymphoma, high-grade non-Hodgkin's lymphomas, high tumor burden) • Sufficient rehydration (target: > 2.5 l urine daily) while monitoring CVP • Alkalization (target: urinary pH > 7) with NaHCO3 p.o. or citrate p.o., intravenous bicarbonate (if required) • Xanthine oxidase inhibitors (allopurinol 300 mg/day) → if not tolerated: benzbromarone (uricosuric agent) ATTENTION: allopurinol inhibits the metabolization of 6-mercaptopurine, azathioprine, theophylline, and phenprocoumon → if given with allopurinol, the dose of 6-mercaptopurine must be lowered to 25%. Acute or subacute hemorrhagic inflammation of the mucous membrane of the urinary bladder, usually treatment-induced (cyclophosphamide, ifosfamide, radiotherapy) Hematuria, pollakiuria, pain Bladder irrigation; often spontaneous cessation. Complications occurring after transfusion of cellular blood products (packed red cells and platelet concentrates), fresh frozen plasma (FFP), coagulation factors, immunoglobulins, or human albumin. Transfusion reactions are classified according to pathogenesis, type of blood product, time of occurrence, and clinical picture. Incidence: approximately 1-10% of all transfusions. • Most dangerous form of acute transfusion reactions, incidence 1:6,000 to 1:25,000 transfusions, 0.75 deaths per 100,000 transfusions • Major ABO incompatibility → severe acute intravascular hemolysis with complement activation and cytokine release • In rare cases, irregular preformed antierythrocytic allo-or autoantibodies in the recipient (Kell system, Kidd system, Duffy system, etc.) • Most common transfusion reaction, 5% of all transfusions • Post-transfusion temperature increase by ≥ 1°C with no signs of hemolysis or other transfusion-induced reactions • Pathogenesis: antibodies against platelets or leukocytes, active mediator release from viable leukocytes contained in the blood product (e.g., cytokines), bacterial contamination (very rare) • Local or generalized allergic reaction to plasma proteins • In case of local urticarial reaction: transfusion may be continued after antihistamine treatment (all other cases of transfusion reactions: stop the transfusion, return blood product to blood bank, see below) • Patients with congenital IgA deficiency (incidence 1:700) and presence of IgA antibodies. In the majority of cases, pathogenesis not clear. • Granulocyte-or monocyte-specific antibodies (HLA class I or II) in the donor plasma react with leukocyte antigens in the recipient (in rare cases, reverse antibody constellation) → agglutination and activation of granulocytes and monocytes, especially in the lungs • Rare and potentially fulminant ARDS-like reaction occurring 1-6 h after transfusion; lethal in approximately 15% • Citrate intoxication ( . Transfusion Reactions Extravasation / paravascular administration of cytostatic drugs. Extravasation in 0.1-0.5% of all cases of intravenous administration of cytostatic drugs. Cytomegalovirus (CMV) Leukocyte-depleted cellular blood products are equally low risk as anti-CMV-negative blood products (according to guidelines). However, high-risk patients (e.g., anti-CMV-negative recipient of allogenic stem cell transplant, intrauterine transfusion) should strictly receive anti-CMV-negative blood products • CMV reactivation / CMV coinfection in anti-CMV-positive immunosuppressed recipients by administration of blood products is unlikely PV-B19): transfusions from PV-B19-IgG-positive donors recommended in patients needing regular transfusions • HTLV I/II: risk identification and sequential testing of donors for HTLV I/II is recommended • EBV (Epstein-Barr virus hepatitis G virus): relevance in relation to transfusions as yet uncertain • TTV (transfusion-transmitted virus): isolated in 1998, significance as yet uncertain Other Transfusion Relevant Infectious Agents • Bacteria: bacterial contamination is rare with sterile preparation and use of single-use materials • Parasitic diseases: malaria, babesiosis, Chagas' disease etc; preventable by temporary abstinence from blood donation after travel to affected regions CJD) / new variant CJD (vCJD): so far, no scientific data on transmission through blood products, however this possibility can not be definitively excluded. Individuals potentially at risk of CJD infection due to their medical history (e.g., treatment with human growth hormone derived from pituitary glands of corpses Pathophysiology of hemolytic transfusion reactions New technology for transfusion safety Risks of transfusion-transmitted infections Transfusion Reactions Transfusion-associated graft-versus-host disease Transfusion-related acute lung injury Hematological and Oncological Emergencies Emergency Treatment Check pulse, local symptoms, and vital signs every 30 min Immediate therapy-even if no symptoms 1. Basic measures: • Stop infusion immediately • Place 5-ml syringe on i.v. access and extract extravasated fluid if possible Substance-specific measures: • Anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), anthracenediones (mitoxantrone), platinum compounds (cisplatin, carboplatin), and mitomycin C: DMS0 99% every 3-4 h for at least 3 days (up to 14 days) → apply with swab to the entire extravasation area and leave to dry. • Anthracyclines: dexrazoxane hydrochloride 1000 mg/m2/d i.v. 24 h and 48 h after extravasation Exception: etoposide, teniposide, vinblastine, vincristine, and vindesine: mild dry warmth (use blanket to keep extravasation site warm) Surgical measures: • Progressive necrosis / ulceration: surgical debridement / removal of necrotic tissue / plastic surgery (flap) Documentation: • All cases of extravasation as well as management and treatment must be accurately documented. may even cause additional toxicity: • Local application of corticosteroids, topical or subcutaneously (highly controversial • Local infiltration of hyaluronidase • Local infiltration of NaHCO3 8.4%, sodium thiosulfate, or heparin (particularly with vinca alkaloids) cytostatic drugs: • For peripheral line: only use veins on the dorsum of the forearm, ensure good flow • Only use intravenous catheters • In patients with history of mastectomy, use contralateral arm for infusion (due to impaired lymph drainage and venous congestion after axillary dissection Px: • Ensure correct position of the intravenous line (erythema, swelling, induration, local pain); if in doubt: resite the i.v. line • Reliable fixation of the extremity, leave access visible • If placement of intravenous line was unsuccessful at first attempt, avoid puncturing the same vein distal to the original access point • Cytostatic drugs should only be added to a freely running infusion (NaCl 0.9% or glucose 5%); of cytostatic drugs of severe local toxicity via peripheral line Extravasation and tissue necrosis due to central line infusions Extravasation of systemic hemato-oncological therapies Extravasation of chemotherapeutic agents: prevention and treatment Totally implantable venous-access ports: local problems and extravasation injury Surgical treatment of extravasation injuries Extravasation: a dreaded complication of chemotherapy Managing vesicant extravasations Ref: Web: Web: . Extravasation of Cytostatic Drugs Prophylactic treatment with mesna after cyclophosphamide / ifosfamide therapy. Severe hemorrhage may require surgery. Coughing up of large quantities of blood (bright red and foamy = arterial, dark = venous), usually vascular erosion by malignant tumor.Emergency bronchoscopy, if possible: local coagulation, blockade / tamponade with balloontipped catheter Vomiting of large quantities of blood, due to a bleeding malignant tumor, hemorrhagic gastritis / mucositis, vascular erosion.Endoscopy, local coagulation, if necessary: emergency surgery Hemorrhage in the upper gastrointestinal tract (melena) or lower gastrointestinal tract (bright red blood in stools). • Retain blood bag (forensic reasons) • Return blood bag and a recent blood sample of the patient to the blood bank → Retesting of serological compatibility (before/after reaction), ABO compatibility between blood product and patient's blood, direct antiglobulin test, screening for irregular antibodies, bacteriological examination of the blood product Supportive treatment (depending on the severity / cause of the reaction): oxygen, blood pressure, stabilization, diuresis maintenance with fluids and/or osmodiuretics (mannitol); TRALI: early ventilation support may be required Prednisolone 100 mg i.v., alternatively: dexamethasone 8 mg i.v. • Volume substitution, alkalinization, monitoring of urinary output to prevent acute renal failure; with impending acute renal failure: hemodialysis; ATTENTION: hyperkalemia due to potassium release from erythrocytes • Continued antiallergic treatment: steroids, antihistamines • Close monitoring of coagulation parameters, exclusion of DIC (7 Chap. 6.5.5) ATTENTION: do not underestimate the dynamics of acute transfusion reactions. Patients may require intensive care from an early stage. • Development of platelet-specific alloantibodies → severe thrombocytopenia approximately 5-9 days after transfusion involving the patient's own platelets ("innocent bystander"), usually occurring in women between 50 and 70 years of age • Treatment: intravenous IgG (avoid platelet transfusion) • Primary immunization or boosting of alloantibodies → delayed hemolysis, usually few clinical symptoms • Diagnosis: immunohematological re-examination, hemolytic parameters Reaction of proliferating donor T-lymphocytes to the recipient; occurring with transfusion of immunosuppressed patients and transfusion of blood relatives ("one-way HLA match") • Engraftment of transfused cells • Later: transfusion-associated graft-versus-host disease (tGvHD) • After latent period of 20-60 days, skin manifestations (dermatitis), intestinal symptoms (gastroenteritis), hepatitis; often not associated with transfusion due to latency period, mortality rate of up to 90% • Diagnosis: detection of donor lymphocytes, DNA fingerprinting, skin biopsies • Prophylaxis: irradiation of blood products (indications: 7 Chap. 4.9.1) Iron deposition in the tissue due to iron overload by a factor of ≥ 5 (normal iron level: men 3.5 g, women 2.2 g). Rule of thumb: in chronically transfused patients risk of hemosiderosis after ≥ 100 packed red cell transfusions (approximately 250 mg iron per transfusion).Symptoms depending on the affected organs: • Hepatic dysfunction, diabetes mellitus, endocrine disturbances • Dark pigmentation of the skin ("bronze diabetes") • Cardiomyopathy, arrhythmia Risk with cellular products: < 1: 1,000,000 → further minimized due to introduction of HIV genome testing of donors by nucleic acid amplification; significantly lower risk with cell-free products (FFP, immunoglobulins, and coagulation factor products) due to quarantine or virus inactivation. Risk with cellular products: 1:50,000 to 1:200,000; significantly lower risk with cell-free products (due to quarantine or virus inactivation). Risk with cellular products: < 1:500,000; risk minimization possible by statutory nucleic acid amplification testing (HCV-NAT) of cellular blood products; significantly lower risk with cell-free products (due to quarantine or virus inactivation).